Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Myrbetriq (Mirabegron) – Treatment for Overactive Bladder (OAB)

Drug (Brand / Generic)

Myrbetriq / mirabegron

Company / Licensee

Astellas Pharma

Therapy Class

Beta 3-adrenergic agonist

Current Indication

Overactive bladder (OAB)

Market Sector

Nephrology

Development Status

Approved in Japan and US
Expand
Close
Close
Close

Go Top